Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.32 |
| ▸ | MAPT | P10636 | 6/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NPY2R | P49146 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30137998 | 0.83 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL27980034 | 0.81 | LRRK2 (0.34) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL25018637 | 0.81 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL27765464 | 0.81 | L3MBTL1 (0.32) | MEN1KMT2AALDH1A1MAPTELANE | |
| SCHEMBL27229257 | 0.79 | ALDH1A1 (0.32) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL18049673 | 0.77 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL25019061 | 0.77 | SMN1; SMN2 (0.38) | ALDH1A1MAPTPOLBL3MBTL1HTT | |
| SCHEMBL20652286 | 0.75 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL31052716 | 0.75 | AADAT (0.35) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL30267448 | 0.73 | KMT2A (0.40) | MEN1KMT2AALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150592-B1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3150592-B1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3150592-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | Beijing Pearl Biotechnology Limited Liability Company (CN) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150592-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | Beijing Pearl Biotechnology Limited Liability Company (CN) | 2017-04-05 | — | — | EP | disclosed |
| CN-105294654-A | ALK kinase inhibitor as well as preparation method and application thereof | BEIJING PEARL BIOTECHNOLOGY LTD LIABILITY COMPANY | 2016-02-03 | — | — | CN | disclosed |
| WO-2015180685-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | 北京浦润奥生物科技有限责任公司 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | ALK, BRAF, ABL1 | MEN1 1644/4885KMT2A 668/4885ALDH1A1 679/4885 |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | ALK, BRAF, ABL1 | MEN1 1644/4885KMT2A 668/4885ALDH1A1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.